Efficacy and safety of pyronaridine-artesunate for treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 3884-3890

  Leang, Rithea ^a   Canavati, Sara E ^b   Khim, Nimol ^c   Vestergaard, Lasse S ^d   Borghini Fuhrer, Isabelle ^e   Kim, Saorin ^c   Denis, Mey Bouth ^d   Heng, Pisal ^a   Tol, Bunkea ^a   Huy, Rekol ^a   Duparc, Stephan ^e   Dondorp, Arjen M ^b   Menard, Didier ^c   Ringwald, Pascal ^d  

^a National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^b MAHIDOL UNIVERSITY   (Thailand)

^c INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTEMETHER; ARTESUNATE PLUS PYRONARIDINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; QUININE; TETRACYCLINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; NAPHTHYRIDINE DERIVATIVE; PYRONARIDINE;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY WEIGHT; CAMBODIA; CHILD; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; FOLLOW UP; GENOTYPE; GOOD CLINICAL PRACTICE; HEADACHE; HEARING IMPAIRMENT; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT INFECTION; SIDE EFFECT; TACHYCARDIA; TINNITUS; TREATMENT FAILURE; TREATMENT RESPONSE; URINE COLOR; VERTIGO; VOMITING; KAPLAN MEIER METHOD; MALARIA, FALCIPARUM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CAMBODIA; CHILD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; NAPHTHYRIDINES; YOUNG ADULT;

EID: 84976907427     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00039-16     Document Type: Article

References (29)

1. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, Incardona S, Lim P, Sem R, Socheat D, Christophel EM, Ringwald P. 2006. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 11:1360-1366. http://dx.doi.org/10.1111/j.1365-3156.2006.01690.x.
2. Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, Tsuyuoka R, Maguire JD, Fandeur T, Ariey F, Wongsrichanalai C, Meshnick SR. 2007. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 76:641-647.
3. Shah NK, Alker AP, Sem R, Susanti AI, Muth S, Maguire JD, Duong S, Ariey F, Meshnick SR, Wongsrichanalai C. 2008. Molecular surveillance for multidrug-resistant Plasmodium falciparum, Cambodia. Emerg Infect Dis 14:1637-1640. http://dx.doi.org/10.3201/eid1410.080080.
4. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, Saingam P, Buathong N, Sriwichai S, Chann S, Se Y, Yom Y, Heng TK, Kong N, Kuntawunginn W, Tangthongchaiwiriya K, Jacob C, Takala-Harrison S, Plowe C, Lin JT, Chuor CM, Prom S, Tyner SD, Gosi P, Teja-Isavadharm P, Lon C, Lanteri CA. 2015. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother 59:4631-4643. http://dx.doi.org/10.1128/AAC.00366-15.
5. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, Kim S, Witkowski B, Duru V, Domergue A, Khim N, Ringwald P, Menard D. 2015. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59:4719-4726. http://dx.doi.org/10.1128/AAC.00835-15.
6. Saunders DL, Vanachayangkul P, Lon C, US Army Military Malaria Research Program, National Center for Parasitology, Entomology, and Malaria Control, Royal Cambodian Armed Forces. 2014. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 371:484-485. http://dx.doi.org/10.1056/NEJMc1403007.
7. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
8. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
9. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TJ, Fay MP, Mu J, Duong S, Fairhurst RM. 2012. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 12:851-858. http://dx.doi.org/10.1016/S1473-3099(12)70181-0.
10. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50-55. http://dx.doi.org/10.1038/nature12876.
11. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371:411-423. http://dx.doi.org/10.1056/NEJMoa1314981.
12. Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio JJ, Pfrender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K. 2015. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520:683-687. http://dx.doi.org/10.1038/nature14412.
13. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Menard D, Fidock DA. 2015. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347:428-431. http://dx.doi.org/10.1126/science.1260867.
14. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul M, Sia-ngam P, Kuntawunginn W, Arsanok M, Buathong N, Chaorattanakawee S, Gosi P, Ta-aksorn W, Chanarat N, Sundrakes S, Kong N, Heng TK, Nou S, Teja-isavadharm P, Pichyangkul S, Phann ST, Balasubramanian S, Juliano JJ, Meshnick SR, Chour CM, Prom S, Lanteri CA, Lon C, Saunders DL. 2015. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 15:683-691. http://dx.doi.org/10.1016/S1473-3099(15)70049-6.
15. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, Lim P, Mead D, Oyola SO, Dhorda M, Imwong M, Woodrow C, Manske M, Stalker J, Drury E, Campino S, Amenga- Etego L, Thanh TN, Tran HT, Ringwald P, Bethell D, Nosten F, Phyo AP, Pukrittayakamee S, Chotivanich K, Chuor CM, Nguon C, Suon S, Sreng S, Newton PN, Mayxay M, Khanthavong M, Hongvanthong B, Htut Y, Han KT, Kyaw MP, Faiz MA, Fanello CI, Onyamboko M, Mokuolu OA, Jacob CG, Takala-Harrison S, Plowe CV, Day NP, Dondorp AM, Spencer CC, McVean G, Fairhurst RM, White NJ, Kwiatkowski DP. 2015. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 47:226-234. http://dx.doi.org/10.1038/ng.3189.
16. Basco LK, Le Bras J. 1994. In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives. Ann Trop Med Parasitol 88:137-144.
17. Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, Fleckenstein L. 2013. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J 12:70. http://dx.doi.org/10.1186/1475-2875-12-70.
18. Kayentao K, Doumbo OK, Penali LK, Offianan AT, Bhatt KM, Kimani J, Tshefu AK, Kokolomami JH, Ramharter M, de Salazar PM, Tiono AB, Ouedraogo A, Bustos MD, Quicho F, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L. 2012. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J 11:364. http://dx.doi.org/10.1186/1475-2875-11-364.
19. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Belard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmuller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG. 2008. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 198:911-919. http://dx.doi.org/10.1086/591096.
20. Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, Penali LK, Valecha N, Tien NT, Abdulla S, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Pyronaridine-Artesunate Study Team. 2012. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 366:1298-1309. http://dx.doi.org/10.1056/NEJMoa1007125.
21. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Pyronaridine-Artesunate Study Team. 2010. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised noninferiority trial. Lancet 375:1457-1467. http://dx.doi.org/10.1016/S0140-6736(10)60322-4.
22. World Health Organization. 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/.
23. World Health Organization. 2008. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. World Health Organization, Geneva, Switzerland.
24. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L. 2011. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 6:e14501. http://dx.doi.org/10.1371/journal.pone.0014501.
25. Basco LK, Ringwald P. 2003. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 47:1391-1394. http://dx.doi.org/10.1128/AAC.47.4.1391-1394.2003.
26. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, Day NP, de Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WR, Nosten F, White NJ. 2010. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201:570-579. http://dx.doi.org/10.1086/650301.
27. World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd ed. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127-eng.pdf.
28. European Medicines Agency. 2012. European Medicines Agency recommends new antimalaria treatment for use outside the European Union. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2012/02/WC500122946.pdf. European Medicines Agency, London, United Kingdom.
29. ICH. 1996. ICH harmonised tripartite guideline. ICH, Geneva, Switzerland. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdfcy/E6/E6-R1-Guideline.pdf.